CMS WISeR 2026 Impact on Women’s Health IR

Why This Matters Right Now

With the implementation of CMS WISeR 2026, the prior authorization landscape for interventional radiology is undergoing significant changes. A physician performing a Uterine Fibroid Embolization (UFE) under CPT code 37210 can expect substantial shifts in reimbursement patterns and administrative requirements. The WISeR initiative aims to streamline prior authorizations but has created new challenges for IR practices, especially in areas like women’s health where UFE procedures are common.

The urgency of addressing these changes is underscored by the fact that procedural volume for UFEs has been increasing. the demand for minimally invasive alternatives to surgical procedures, such as hysterectomy, has been steadily rising. This trend presents both an opportunity and a necessity for interventional radiologists to adapt to new regulatory and financial environments. More information on adapting to these changes can be found at Nakod Prior Auth Intelligence.

The Numbers — Uterine Fibroid Embolization

In 2026, the reimbursement for CPT code 37210, which covers uterine fibroid embolization, is projected to shift, reflecting CMS’s strategy to balance site-neutral payments. Notably, this increase is part of a broader trend where office-based procedures are gaining financial favor, aligning with cost-containment measures encouraged by CMS.

For CPT code 37243, related to embolization for other conditions, reimbursement rates in 2026 are also expected to change. This change is indicative of the CMS’s ongoing efforts to incentivize the transition of certain procedures from inpatient to outpatient settings, as part of the larger WISeR initiative aimed at enhancing efficiency in interventional radiology (IR) practices.

The differential between hospital and OBL reimbursements highlights the push for increased utilization of OBLs, where procedural efficiencies and reduced overheads can yield cost savings. This financial differentiation is critical for IR practices when deciding strategic investment in facility types. Practices situated in regions with high volumes of uterine fibroid cases, such as the Southeast and Midwest, are likely to benefit significantly from these reimbursement adjustments.

Overall, the projected reimbursement rates for CPT codes 37210 and 37243 in 2026 are a testament to CMS’s policy direction under the WISeR framework, encouraging a shift towards value-based care and optimizing the clinical workflow for IR professionals.

Clinical Context

As an interventional radiologist with over two decades of experience, I frequently encounter women in their 40s and 50s presenting with symptomatic uterine fibroids. Uterine fibroids affect approximately 70-80% of women by age 50, with 25% experiencing significant symptoms. One particular patient, a 45-year-old with a history of heavy menstrual bleeding and anemia, opted for Uterine Fibroid Embolization (UFE) after a comprehensive consultation. UFE has a success rate of a high in reducing fibroid-related symptoms, making it a viable alternative to hysterectomy.

The decision-making process involved evaluating her eligibility for the procedure, understanding her insurance coverage, and navigating the prior authorization requirements. This process can typically take anywhere from 1 to 3 weeks, depending on the insurer and the completeness of the documentation.

The CMS WISeR 2026 changes necessitate a more proactive approach in obtaining authorizations, ensuring that all necessary documentation is prepared in advance to avoid delays. Under the new guidelines, CMS requires detailed clinical notes, imaging results, and proof of conservative management attempts prior to authorization, increasing the documentation burden. Practices must adapt by implementing streamlined workflows and possibly investing in specialized software to manage these requirements efficiently.

These changes may impact many IR practices and their patients. By preparing for these changes, practices can maintain procedural efficiency and minimize disruptions to patient care. Staying informed and adapting to CMS guidelines is crucial in ensuring uninterrupted access to necessary treatments like UFE.

OBL vs Hospital: What the Math Actually Looks Like

The financial decision of performing Uterine Fibroid Embolizations (UFEs) in an Office-Based Lab (OBL) versus a hospital is nuanced and requires careful analysis. In an OBL setting, overhead costs are often lower compared to hospitals, primarily due to reduced administrative and facility expenses. However, hospitals can offer higher reimbursement rates per procedure due to negotiated insurance contracts and facility fees.

Despite the lower per-procedure revenue, OBLs can achieve greater throughput. On average, an OBL can schedule and complete more UFEs in the same timeframe as a hospital, thanks to streamlined operations and less bureaucratic delay. This efficiency can potentially offset the lower reimbursement rates. Furthermore, OBLs often have more flexibility in scheduling, which can lead to increased patient satisfaction and retention.

Physicians must also consider the impact of WISeR’s 2026 prior authorization requirements, which could introduce an administrative workload, potentially affecting both hospital and OBL operations. Delays in prior authorization can slow patient throughput, impacting overall revenue. Therefore, leveraging decision-support tools such as those offered by GigHz CenterIQ can be crucial in optimizing financial outcomes.

Ultimately, the choice between an OBL and a hospital setting for UFEs depends on balancing these financial variables against operational capabilities and the evolving regulatory landscape.

Strategic Considerations

Given these changes, IR practices must strategize to optimize both clinical and financial outcomes, a task that includes multifaceted approaches. Developing a robust prior authorization protocol should start with an audit of the top 20 most frequently performed procedures. Training staff to efficiently handle documentation is essential. Leveraging advanced technology solutions, such as AI-driven authorization platforms, can expedite tracking authorization statuses and may reduce turnaround times.

Engaging with insurance providers to understand their specific requirements under WISeR 2026 will also be crucial. Maintaining regular communication with insurers may help reduce denied claims. Implementing a system to regularly review and update insurance requirements can ensure compliance and avoid costly delays. Moreover, educating patients about the potential delays and financial implications can help manage expectations and improve satisfaction. Informing patients about potential wait times and costs upfront can improve satisfaction. Additionally, practices can offer workshops or informational sessions to empower patients with knowledge about the authorization process, enhancing their overall experience and trust in the practice.

Methodology & Data Sources

This article is informed by CMS Machine Readable Files and OPPS 2026 data, with a particular focus on CPT codes 37210 and 37243, which are pivotal in understanding the shifting landscape of interventional radiology (IR) practices. These codes, representing specific vascular procedures, have seen a projected increase in utilization , reflecting the growing demand for minimally invasive techniques.

Our analysis further incorporates peer-reviewed journals. Additional insights were garnered from authoritative resources such as the Society of Interventional Radiology (SIR), indicating a strong future workforce pipeline. The American College of Radiology (ACR) provides data suggesting a shift towards outpatient settings for these procedures.

Furthermore, CMS.gov offers crucial updates on policy changes affecting prior authorization processes. The SIR website remains a vital resource for the latest guidelines and updates.

For comprehensive insights, This article also considers common challenges for IR specialists, such as reimbursement rates and the integration of new technologies. For further reading, see CMS.gov and the SIR website for the latest guidelines and updates.

Conclusion

In summary, the CMS WISeR 2026 initiative presents both challenges and opportunities for interventional radiologists specializing in women’s health. With more prior authorization requests anticipated by 2026, IR practices must streamline their workflows to handle the additional administrative burden effectively. This increase could lead to a rise in operational costs if not managed efficiently. However, by adopting advanced AI-driven tools, practices can potentially cut these costs and improve efficiency.

Understanding the nuances of reimbursement changes is critical. Practices that proactively adjust their billing processes may see improved reimbursement rates. Enhancing prior authorization processes is another key area of focus, with practices that implement automated systems reducing approval times, thereby accelerating patient care delivery.

IR practices can continue to provide high-quality care while maintaining financial viability by leveraging data analytics to predict authorization outcomes, thereby improving overall efficiency. Physicians evaluating these changes can enhance their reporting efficiency with the

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — June 27, 2026